Olema Slides as AstraZeneca Breast Cancer Trial Misses Goal

Olema Pharmaceuticals shares fell 15.1% in premarket trading on September 14 to $8.68, putting the spotlight on a clinical readout that did not involve the company directly but struck at the rationale behind its lead drug.

AstraZeneca said September 11 that its Phase 3 SERENA-4 trial failed to produce a statistically significant improvement in progression-free survival for camizestrant, now branded Etcamah, when combined with palbociclib as an initial treatment for patients with estrogen receptor-positive, HER2-negative advanced breast cancer. The study compared that regimen with anastrozole plus palbociclib. AstraZeneca said the camizestrant combination showed a numerical improvement, but not one that cleared the trial’s statistical threshold.

The concern for Olema is mechanistic. Its lead candidate, palazestrant, is also an oral selective estrogen receptor degrader and complete estrogen receptor antagonist, a drug profile intended to suppress estrogen signaling more directly than standard endocrine therapies. Investors are now asking whether the setback reflects a problem with camizestrant’s particular molecule or a broader challenge for the class, especially in earlier-line treatment.

That distinction matters. SERENA-4 tested AstraZeneca’s drug in the first-line setting, while Olema’s most immediate catalyst is OPERA-01, a Phase 3 study testing palazestrant as a monotherapy in second- and third-line metastatic breast cancer. Olema expects to report top-line OPERA-01 results in the fall of 2026, according to its latest corporate update.

The company is also running OPERA-02, which evaluates palazestrant with Novartis’s ribociclib in front-line metastatic breast cancer. That program now faces a tougher evidence backdrop, even though SERENA-4 cannot establish whether palazestrant will succeed in either trial.

Stifel cut its price target on Olema to $30 from $48 while retaining a Buy rating, according to the wire report. The downgrade sharpened the market’s focus on the binary nature of the upcoming data. Olema had $461.1 million in cash, cash equivalents and marketable securities at June 30, but reported a second-quarter net loss of $63.2 million as spending increased on late-stage trials.